Related Experiment Video

Updated: Apr 27, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.8K

How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia

Michael J Burke1

  • 1Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. mmburke@mcw.edu.

Future Oncology (London, England)
|July 2, 2014
PubMed

Insights

Hypersensitivity to asparaginase, a key drug for acute lymphoblastic leukemia (ALL), can worsen patient outcomes. Prompt identification and management of hypersensitivity are crucial for successful ALL treatment.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Pharmacology

Background:

  • Acute lymphoblastic leukemia (ALL) outcomes have improved with chemotherapy, notably asparaginase.
  • Asparaginase therapy is critical but frequently complicated by hypersensitivity reactions.
  • Treatment interruption due to hypersensitivity is linked to poorer ALL outcomes in children.

Purpose of the Study:

  • To review asparaginase hypersensitivity in pediatric ALL.
  • To discuss identification and management of clinical and subclinical hypersensitivity.
  • To address switching to alternative asparaginase formulations after hypersensitivity.

Main Methods:

  • Literature review on asparaginase hypersensitivity.
  • Analysis of clinical and subclinical hypersensitivity identification strategies.
  • Examination of management protocols for asparaginase hypersensitivity.

Main Results:

  • Hypersensitivity, including silent inactivation, necessitates treatment modification.
  • Early detection of hypersensitivity is vital for maintaining therapeutic efficacy.
  • Switching to Erwinia chrysanthemi asparaginase is a key strategy post-hypersensitivity.

Conclusions:

  • Effective management of asparaginase hypersensitivity is essential for improving pediatric ALL survival rates.
  • Monitoring for and addressing both clinical and subclinical hypersensitivity ensures treatment completion.
  • Optimizing asparaginase therapy through formulation switching improves treatment adherence and outcomes.

Keywords:
acute lymphoblastic leukemiaasparaginaseasparaginase Erwinia chrysanthemihypersensitivitysilent inactivationtherapeutic drug monitoring

More Related Videos

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

684
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

31.0K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
816
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
205
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
547
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
277
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
557
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
401